| Date YYYY-MM-DD |
Board Meeting | Decision Point Number | Title |
|---|---|---|---|
| 2024-04-23 | B51 | GF/B51/DP01 |
Approval of the Agenda Approval of the Agenda
<p>The Agenda for the 51st Board Meeting (GF/B51/01) is approved.</p>
|
| 2024-04-23 | B51 | GF/B51/DP02 |
Approval of the Rapporteur Approval of the Rapporteur
<p>Susan Mochache from the Eastern and Southern Africa constituency is designated as Rapporteur for the 51st Board Meeting.</p>
|
| 2024-04-23 | B51 | GF/B51/DP03 |
Quality Assurance Policy for Vector Control Products Quality Assurance Policy for Vector Control Products
<p>Based on the recommendation of the Strategy Committee, the Board:</p>
<ol type="i">
<li>approves the Quality Assurance Policy for Vector Control Products and Related Equipment as set forth in Annex 1 to GF/B51/05;</li>
<li>requests the Secretariat to work with the World Health Organization (WHO) to establish an Expert Review Panel for Vector Control Products as described in the Policy, and to conclude the necessary arrangements with WHO; and</li>
<li>approves the delegation of authority to the Secretariat, in consultation with the Strategy Committee Chair and Vice Chair, to make non-material adjustments to the Policy in line with Annex 2 to GF/B51/05 and to report back to the Strategy Committee and Board on all such changes.</li>
</ol>
<p>Additionally, while the Board expects efforts will be made to fully implement the Policy upon its approval, the Board understands that for implementation of certain aspects of the Policy a reasonable transition period may be needed. The Board authorizes the Secretariat to allow for such a transition period when needed.</p>
|
| 2024-04-23 | B51 | GF/B51/DP04 |
Global Fund Procurement Policy Update Global Fund Procurement Policy Update
<p>Based on the recommendation of the Audit and Finance Committee, the Board approves:</p>
<ol type="i">
<li>The amended and restated Procurement Policy, which replaces in its entirety the Procurement Policy approved in 2008 through GF/B17/DP21 and the decision point contained in GF/FAC11/03, which sets out the general principles that govern the procurement of goods and services by the Global Fund, as set forth in Annex 1 to GF/B51/20- Revision 1;</li>
<li>Delegation of authority from the Board to the Executive Director for operationalization of the Policy; and</li>
<li>Delegation of authority to the Secretariat, in consultation with the Audit and Finance Committee Chair and Vice Chair, to make non-material adjustments to the procurement policy referenced above, in line with Annex 2 to GF/B51/20- Revision 1 and to report back to the Audit and Finance Committee and Board on all such changes.</li>
</ol>
<p>In addition, the Board requests annual updates from the Secretariat reporting on the operationalization of the amended and restated Procurement Policy and asks the Secretariat to work with the Audit and Finance Committee to agree on the appropriate content for these updates.</p>
|
| 2024-04-24 | B51 | GF/B51/DP05 |
2023 Annual Financial Report 2023 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2023 Annual Financial Report, including the 2023 Annual Financial Statements which have been audited by KPMG SA, as set forth in Annex 1 to GF/B51/14A.</p>
|
| 2024-04-24 | B51 | GF/B51/DP06 |
2023 Statutory Financial Statements 2023 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2023 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B51/14A.</p>
|
| 2024-05-14 | B51 | GF/B51/EDP01 |
Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B51/ER01 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2024-05-14 | B51 | GF/B51/EDP02 |
Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2023-2025 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2023-2025 Allocation Period
<p>The Board:</p>
<ol>
<li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B51/ER01 (“Table 2”);</li>
<li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2024-06-17 | B51 | GF/B51/EDP03 |
Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B51/ER02 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2024-06-17 | B51 | GF/B51/EDP04 |
Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p>
<ol>
<li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B51/ER02 (“Table 2”); and</li>
<li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</li>
</ol>
|
| 2024-07-05 | B51 | GF/B51/EDP05 |
Appointment of Replacement Member on the Audit and Finance Committee Appointment of Replacement Member on the Audit and Finance Committee
<p>The Board approves the appointment of:</p>
<ol>
<li>Sangback Lee, representing the Additional Public Donors Constituency, as a non-voting member of the Audit and Finance Committee for a term that will expire in May 2025, or until the appointment of his successor.</li>
</ol>
|
| 2024-07-05 | B51 | GF/B51/EDP06 |
Decision on the Secretariat’s Recommendation on Grant Extension Decision on the Secretariat’s Recommendation on Grant Extension
<p>The Board:</p>
<ol>
<li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 1 of GF/B51/ER04 (“Table 1”); and</li>
<li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 1, and (b) is subject to the availability of funding. </li>
</ol>
|
| 2024-07-09 | B51 | GF/B51/DP07 |
Extension of Executive Director Term Extension of Executive Director Term
<p>In order to ensure leadership continuity through the 8<sup>th</sup> Replenishment and a robust selection process for the next Executive Director, the Board decides to extend the term of Peter Sands, as the Executive Director of the Global Fund, until the end of 2026 or the commencement of the term of the next Executive Director, if sooner. The next Executive Director is projected to commence his/her term before the end of 2026 and ideally by the November 2026 Board Meeting.</p>
<p>The Board mandates the Chair and Vice-Chair of the Board to attend to the extension of the employment agreement of the Executive Director, with due consideration for a successful transition between the outgoing and incoming Executive Director.</p>
<p>The Board extends its appreciation to Mr. Sands for his service to date as Executive Director and for his dedication to contributing to a successful leadership transition at the end of his tenure as Executive Director.</p>
|
| 2024-10-03 | B51 | GF/B51/EDP10 |
Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B51/ER07 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2024-07-26 | B51 | GF/B51/EDP07 |
Approval of the Report of the 51st Board Meeting Approval of the Report of the 51st Board Meeting
<p>The Board approves the Report of the 51st Board Meeting, as set forth in GF/B51/22.</p>
|
| 2024-08-08 | B51 | GF/B51/EDP08 |
Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Tables 1a and 1b of GF/B51/ER05 (“Tables 1a and 1b”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li>
</ol>
|
| 2024-08-30 | B51 | GF/B51/EDP09 |
Additional Catalytic Investment Priority for the 2023-2025 Allocation Period: Climate and Health Additional Catalytic Investment Priority for the 2023-2025 Allocation Period: Climate and Health
<p>Based on the recommendation of the Strategy Committee, the Board:</p>
<ol>
<li>Recalls its approval of the catalytic investment priorities for the 2023-2025 allocation period as set forth in Annex 1 of GF/B48/03A-Revision 1 (“2023-2025 Catalytic Investment Priorities”); and</li>
<li>Approves the inclusion of a new priority for “Climate and Health” as one of the 2023-2025 Catalytic Investment Priorities to support implementation of the Global Fund’s Strategic Objectives.</li>
</ol>
|
| 2024-10-29 | B51 | GF/B51/EDP11 |
Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B51/ER08 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2024-10-29 | B51 | GF/B51/EDP12 |
Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2023-2025 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2023-2025 Allocation Period
<p>The Board:</p>
<ol>
<li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B51/ER08 (“Table 2”);</li>
<li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2024-11-05 | B51 | GF/B51/EDP13 |
Increasing the Grant Cycle 7 Emergency Fund Increasing the Grant Cycle 7 Emergency Fund
<p>The Board:</p>
<ol>
<li>Recalls its decision to delegate authority to the Secretariat to increase the amount allocated to the grant cycle 7 Emergency Fund catalytic investment priority for the 2023-2025 allocation period by up to 50% of the amount approved for this priority, pursuant to decision point GF/B47/DP06 (May 2022), using funding made available by the Audit and Finance Committee for portfolio optimization;</li>
<li>Acknowledges the need for additional funding above the delegated authority of 50% of the approved priority amount of US$12 million;</li>
<li>Approves the reallocation of US$30 million, from portfolio optimization funds approved by the Audit and Finance Committee, pursuant to decision point GF/AFC26/EDP01 (October 2024), to the Emergency Fund; and</li>
<li>Reaffirms its commitment to ensure that the Emergency Fund has sufficient funding to respond swiftly to current and future emergency needs within the Global Fund portfolio.</li>
</ol>
|
| 2024-11-19 | B51 | GF/B51/EDP14 |
Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 and Table 2 of GF/B51/ER10 (“Table 1” and “Table 2”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1 and Table 2, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2024-11-19 | B51 | GF/B51/EDP15 |
Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2023-2025 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2023-2025 Allocation Period
<p>The Board:</p>
<ol>
<li>Approves the revised budget recommended for the grants listed in Table 3 of GF/B51/ER10 (“Table 3”);</li>
<li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2024-11-19 | B51 | GF/B51/EDP16 |
Appointment of Replacement Members on the Audit and Finance Committee and the Strategy Committee Appointment of Replacement Members on the Audit and Finance Committee and the Strategy Committee
<p>The Board approves the appointment of:</p>
<ol>
<li>Paul Dockery, representing the Point Seven Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2025, or until the appointment of his successor;</li>
<li>Clara Brandt, representing the Point Seven Constituency, as a voting member of the Strategy Committee for a term that will expire in May 2025, or until the appointment of her successor; and</li>
<li>Lee Abdelfadil, representing the UNAIDS Constituency, as a non-voting member of the Strategy Committee for a term that will expire in May 2025, or until the appointment of her successor.</li>
</ol>
|